Recently released first report of DESTINY‐Breast04 has brought us exciting positive results that trastuzumab‐deruxtecan (DS‐8201) could almost double the progression‐free survival in advanced HER2‐low breast cancer patients compared with regular treatment.14 This evidence concerns the gene ERBB2 and breast carcinoma.